In this article, Ben van der Schaaf, principal at Arthur D. Little, gives a five-step guide to explore possible funding partnerships for lower-priority drug trials — a new model for big pharma.
Speed to market is a significant concern in tablet manufacturing, however, moving too quickly may cause problems. Here, Dr Charles Kettler and Robert Sedlock reveal anticipatory experiments to help make the transition from R&D to full scale smooth.
Dr Rajendra Wable, subject matter expert-medical writing and regulatory affairs at Sciformix Corporation, discusses how marketing authorisation applications across Europe, Australia and other countries can be supported with non-clinical overviews
Drug discovery and development company, AiCuris, has been granted fast track designation by the US FDA for oral pritelivir — its lead candidate for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised adults.
A recent study from Zebra Technologies has revealed that manufacturers are investing in wearable technologies to eliminate pen and paper from supply chains
Dr Prashanth BSB, head of safety and medical writing for ELC Group, talks to EPM about the ramifications Brexit may have on the pharmacovigilance landscape.
As pharma anticipates the forthcoming Brexit negotiations and future uncertainty, Stephie Castling, senior marketing executive from Denny Bros, examines the regulatory concerns coming to the fore in the industry.
CPhI Worldwide, organised by UBM, have announced the panel for the 2017 Annual Industry Report, which will represent the fifth edition. As such, a decision has been made to review the past five years’ reports to see how accurate the predictions were.
Dr Marisa Miraldo, associate professor in Health Economics at Imperial College Business School, London, discusses ways to accelerate innovation in healthcare for the benefit of patients, healthcare providers and industry.
Focusing on the keys to success for contract drug manufacturers, Arnaud Sergent, Serge Hovsepian, Nohmie Ben Rekassa and Ben Faircloth from L.E.K. Consulting detail the differentiation strategies that have proven themselves in the marketplace
R&D efficiency has been in decline for many years, but now with bodies, like the FDA, aiming to accelerate approval times and a critical need for new therapies to combat antibiotic resistant strains of bacteria will we see the tide turn?
